Transaction Overview: Acquisition of Korean Biotech to Create Bitcoin Treasury Company
New York-based investment firm Parataxis Holdings LLC has announced a definitive agreement to acquire a controlling interest in South Korean biotech company Bridge Biotherapeutics Inc. (KOSDAQ: 288330) for KRW 25 billion (approximately $18.3 million). This transaction effectively creates South Korea's first institutionally backed Bitcoin treasury company. Upon completion, Bridge Biotherapeutics will be renamed Parataxis Korea and continue trading on the KOSDAQ exchange, subject to shareholder approval and customary closing conditions.
Founded in 2015, Bridge Biotherapeutics is a clinical-stage biotech firm developing therapeutics for ulcerative colitis, fibrotic diseases, and cancers. The acquisition will transform the company into a hybrid entity that maintains its existing therapeutic development programs while establishing a dedicated Bitcoin treasury. This structure allows the firm to retain its core biotech capabilities while adopting a corporate Bitcoin accumulation strategy similar to that of MicroStrategy (now Strategy) in the US and Metaplanet in Japan.
Corporate Transformation and Management Changes
As part of the deal, both the company's name and management team will be restructured. Edward Chin, Founder and CEO of Parataxis Holdings and Co-Founder & CEO of Parataxis Capital, will join Bridge Bio's board of directors following the transaction's completion. Andrew Kim, Partner at Parataxis Capital, will assume the role of CEO of Parataxis Korea and also join the board. Bridge Bio co-founder James Jungkue Lee will continue leading the core biotech business, ensuring continuity of ongoing research and development programs.
Edward Chin emphasized that this arrangement preserves the company's existing R&D strengths while bringing in specialized management for the Bitcoin treasury initiative. Andrew Kim will be responsible for establishing and operating the Bitcoin treasury, while simultaneously overseeing the biotech business's normal progress. The dual focus is intended to maximize shareholder value by combining a stable biotechnology operation with the potential upside of Bitcoin appreciation.
Global Context of Bitcoin Treasury Strategy and Significance for South Korea
Andrew Kim explained the strategic rationale behind the acquisition: "Inspired by the growing interest in BTC treasury strategies seen in companies like Strategy in the US and Metaplanet in Japan, we believe institutional interest in this space is increasing globally. We see South Korea as an important market in the evolution of BTC adoption. Our intent is to support institutional access to BTC exposure while emphasizing sound corporate governance and disciplined capital management." He added that Parataxis Korea aims to become a benchmark for compliant and transparent Bitcoin treasury operations in the region.
Edward Chin provided a longer-term perspective: "We are incredibly excited to create the first BTC treasury company in South Korea backed by an institutional-grade platform. Given the strategic nature of BTC on the global stage and its finite supply, we believe that building and growing a company like Parataxis Korea and accumulating a BTC treasury will benefit our shareholders as well as the country over the long run." This statement aligns with the growing trend of publicly listed companies using debt or equity financing to accumulate Bitcoin, as seen in the US and Japan. The finite supply of Bitcoin (21 million cap) is often cited as a key value proposition for corporate treasuries seeking to hedge against inflation and currency depreciation.
Transaction Timeline and Advisory Team
The transaction's completion is subject to approval by Bridge Biotherapeutics shareholders at a special meeting scheduled for August. At that meeting, shareholders will vote on the acquisition agreement. Legal advisory services are provided by Shin & Kim LLC, a prominent Korean law firm with cross-border M&A expertise, while Deloitte serves as financial advisor. Both firms have extensive experience in cryptocurrency-related corporate transactions, ensuring the deal's regulatory compliance and professionalism.
This acquisition not only introduces South Korea's first "Bitcoin treasury" stock to its capital markets but also provides a reference case for other Asian countries exploring similar corporate treasury strategies. As South Korea's financial regulators continue to refine their virtual asset framework, the establishment of Parataxis Korea could mark a significant milestone for institutional Bitcoin allocation in the country. Market observers note that if successful, this model may encourage other Korean listed companies to follow suit, potentially accelerating corporate Bitcoin adoption across Asia.